You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Staphylococcus aureus Bacteremia and Endocarditis: Making an Impact on Outcomes: The Role of the Patient and the Organism

Weinstein, Robert A. MD

Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e318227e363
NFID Clinical Updates
Abstract

Three scientific approaches to infectious disease-case series, epidemiologic investigation, and molecular analysis-have aided researchers in understanding the evolution of pathogen activity. Four eras of pathogen activity have occurred from 1920 to the present (streptococcus, staphylococci, gram-negative rods, and multidrug-resistant organisms). The emergence of health care-associated and community-associated (CA) methicillin-resistant Staphylococcus aureus (MRSA) infections has resulted in the blurred distinction among the entities. In addition, there are several virulence factors that contribute significantly to the pathogenicity of the organism, and single nucleotide polymorphisms (SNPs) play an important role in determining an individual's response to infection. Health outcomes are significantly worse in MRSA patients compared with uninfected patients or those infected with methicillin-susceptible S. aureus (MSSA). Ongoing molecular research will continue to elucidate mechanisms associated with virulence of MRSA.

Author Information

From the C. Anderson Hedberg, MD, Professor of Internal Medicine, Rush University School of Medicine; and Department of Medicine, Stroger (Cook County) Hospital, Chicago, IL.

Correspondence to: Robert A. Weinstein, MD, Cook County Hospital, Division of Infectious Diseases, 637 S. Wood Street, Chicago, IL 60612-3810. E-mail: rweinste@rush.edu.

This publication is based on a presentation by Dr Weinstein during the 2009 satellite symposium preceding the 47th Annual Meeting of the Infectious Diseases Society of America.

The author has no conflicts of interest to disclose.

This activity is supported by an unrestricted educational grant from Cubist Pharmaceuticals.

© 2011 Lippincott Williams & Wilkins, Inc.